BusinessFibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic CancerBy Nasdaq OMXJun 22, 2017, 2:10 AM UTC
BusinessHemispherx Biopharma Repurposes Ampligen in Immuno-OncologyBy Nasdaq OMXMay 31, 2017, 4:04 PM UTC
BusinessHemispherx Biopharma Repurposes Ampligen in Immuno-OncologyBy Nasdaq OMXMay 31, 2017, 4:04 PM UTC
BusinessThe Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic CancerBy Nasdaq OMXMay 9, 2017, 3:15 PM UTC
BusinessSelecta Biosciences Obtains License for Recombinant Immunotoxin LMB-100 from National Cancer Institute (NCI) for Pancreatic Cancer, Mesothelioma and Other CancersBy Nasdaq OMXMay 2, 2017, 12:00 PM UTC
BusinessHemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016By Nasdaq OMXMar 31, 2017, 10:19 PM UTC
BusinessFibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with ChemotherapyBy Nasdaq OMXFeb 3, 2017, 4:06 PM UTC
BusinessHemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer PatientsBy Nasdaq OMXJan 11, 2017, 1:31 PM UTC
